Madrigal Pharmaceuticals (MDGL) PT Raised to $536 at BofA Securities
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rises after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MDGL Hot Sheet
Price: $399.34 +0.76%
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
22 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
BofA Securities analyst Jason Zemansky raised the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $536.00 (from $529.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Madrigal Pharmaceuticals (MDGL) PT Raised to $743 at Truist Securities
- Procore Technologies, Inc (PCOR) PT Raised to $85 at Stifel
- Madrigal Pharma (MDGL) Tops Q3 EPS by $2.66, Beats on Revenue
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
